CDMO Recipharm announced that it has hired former Koura Global Business Development Director Simon Gardner as Business Development Specialist for pMDIs to assist customers with the transition to LGWP propellants. Recipharm President, Advanced Delivery Systems, Chris Hirst commented, "Vital to a successful transition for our customers is having access to a team of … [Read more...] about Recipharm announces appointment of Simon Gardner as Business Development Specialist, partnership with Oz-UK on LGWP MDIs
People
Avalyn Pharma announces appointment of four executives
After recently raising $175 million for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib, Avalyn Pharma has announced four new executive hires. The new appointments include former Boehringer Ingelheim interstitial lung disease (ILD) expert Craig Conoscenti as Senior VP, clinical development; Jim Bishop as Senior VP, Business Operations; … [Read more...] about Avalyn Pharma announces appointment of four executives
Gossamer Bio names Rainer Zimmermann as VP of Medical Affairs
Gossamer Bio, which is developing its seralutinib DPI for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Rainer Zimmermann as VP of Medical Affairs. Zimmermann was most recently Global Medical Leader, Pulmonary Hypertension, at Janssen. Prior to Johnson & Johnson, Zimmermann served as Global Medical Lead, PH Franchise, at … [Read more...] about Gossamer Bio names Rainer Zimmermann as VP of Medical Affairs
Melissa Rhodes joins Avalyn Pharma as Chief Operating Officer
US-based Avalyn Pharma has announced the appointment of former Aerami Therapeutics Chief Development Officer Melissa Rhodes as Chief Operating Officer, a newly created position. Avalyn, which is developing AP01 inhaled pirfenidone and AP02 inhaled nintedanib for the treatment of pulmonary fibrosis, recently announced the appointment of Howard Lazarus as Chief Medical … [Read more...] about Melissa Rhodes joins Avalyn Pharma as Chief Operating Officer
ENA Respiratory announces new funding, personnel to support Phase 2b study of INNA-051 antiviral nasal spray
ENA Respiratory announced preparations for a Phase 2b study of its INNA-051 pegylated TLR2/6 agonist nasal spray for the prevention of respiratory viruses in people aged 65 and older will be supported by an additional $3.8 million from the US Department of Defense (DOD) as well as by several new clinical appointments. In January 2023, the company said that it had … [Read more...] about ENA Respiratory announces new funding, personnel to support Phase 2b study of INNA-051 antiviral nasal spray
Avalyn names Howard M. Lazarus as Chief Medical Officer
Avalyn Pharma, which is developing inhaled formulations of pirfenidone and nintedanib for the treatment of pulmonary fibrosis, has announced the appointment of former Altavant Sciences Chief Medical Officer Howard M. Lazarus as Chief Medical Officer. Lazarus's previous positions include Medical Expert/Executive Director in Clinical Development and Medical Affairs at … [Read more...] about Avalyn names Howard M. Lazarus as Chief Medical Officer
Resyca announces new Chief Technical Officer, licensing deal with Thaerapy
Soft mist inhaler developer Resyca, a joint venture of Medspray Pharma and Recipharm, has announced the promotion of current Head of Development and Project Management Nicolas Buchmann to Chief Technical Officer. Buchman will take over from Wilbur de Kruijf, who is leaving to serve as CEO of a start-up inhaled drug developer called Thaerapy. Resyca also announced that … [Read more...] about Resyca announces new Chief Technical Officer, licensing deal with Thaerapy
Tiziana announces the promotion of Matthew Davis to Chief Operating Officer
Intranasal foralumab developer Tiziana Life Sciences announced the promotion of its Chief Medical Officer Matthew Davis to Chief Operating Officer. Davis, who joined Tiziana in July 2022, will continue to serve as Chief Medical Officer in addition to his role as COO. His previous experience includes roles at Endo, Lupin, and URL Pharma. According to the company, … [Read more...] about Tiziana announces the promotion of Matthew Davis to Chief Operating Officer
Aerami Therapeutics announces appointment of interim CEO and additional management positions
Aerami Therapeutics has announced the promotion of Joshua Ziel from Chief of Staff and VP, Program Development to Chief Operating Officer and interim CEO. Executive Chairwoman Anne Whitaker had been leading Aerami since the sudden death of CEO Lisa Yañez in May 2023. The company also announced the appointments of Gary Burgess as Chief Medical Officer and Sarah … [Read more...] about Aerami Therapeutics announces appointment of interim CEO and additional management positions
MannKind names Burkhard Blank as Executive VP, R&D, and Chief Medical Officer
Inhaled drug developer MannKind Corporation has announced the appointment of former Acorda Therapeutics Head of R&D and Chief Medical Officer Burkhard Blank as MannKind's new Executive VP, Research & Development, and Chief Medical Officer. At Acorda, he was responsible for Phase 3 development of Inbrija levodopa inhalation powder. Blank was most recently Head … [Read more...] about MannKind names Burkhard Blank as Executive VP, R&D, and Chief Medical Officer